Sandu Pharmaceuticals Beheer

Beheer criteriumcontroles 2/4

Sandu Pharmaceuticals' CEO is Umesh Sandu, appointed in Jun 2018, has a tenure of 6.42 years. total yearly compensation is ₹8.45M, comprised of 94.3% salary and 5.7% bonuses, including company stock and options. directly owns 14.37% of the company’s shares, worth ₹78.23M. The average tenure of the management team and the board of directors is 6.4 years and 1.3 years respectively.

Belangrijke informatie

Umesh Sandu

Algemeen directeur

₹8.4m

Totale compensatie

Percentage CEO-salaris	94.3%
Dienstverband CEO	6.4yrs
Eigendom CEO	14.4%
Management gemiddelde ambtstermijn	6.4yrs
Gemiddelde ambtstermijn bestuur	1.3yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Umesh Sandu's beloning veranderd ten opzichte van Sandu Pharmaceuticals's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	₹15m
Mar 31 2024	₹8m	₹8m	₹15m
Dec 31 2023	n/a	n/a	₹11m
Sep 30 2023	n/a	n/a	₹14m
Jun 30 2023	n/a	n/a	₹12m
Mar 31 2023	₹9m	₹8m	₹15m
Dec 31 2022	n/a	n/a	₹15m
Sep 30 2022	n/a	n/a	₹15m
Jun 30 2022	n/a	n/a	₹16m
Mar 31 2022	₹7m	₹7m	₹16m
Dec 31 2021	n/a	n/a	₹17m
Sep 30 2021	n/a	n/a	₹15m
Jun 30 2021	n/a	n/a	₹15m
Mar 31 2021	₹4m	₹3m	₹11m
Dec 31 2020	n/a	n/a	₹7m
Sep 30 2020	n/a	n/a	₹6m
Jun 30 2020	n/a	n/a	₹4m
Mar 31 2020	₹4m	₹3m	₹7m
Dec 31 2019	n/a	n/a	₹7m
Sep 30 2019	n/a	n/a	₹6m
Jun 30 2019	n/a	n/a	₹7m
Mar 31 2019	₹4m	₹3m	₹7m
Dec 31 2018	n/a	n/a	₹9m
Sep 30 2018	n/a	n/a	₹14m
Jun 30 2018	n/a	n/a	₹14m
Mar 31 2018	₹3m	₹3m	₹6m

Compensatie versus markt: Umesh's total compensation ($USD100.46K) is above average for companies of similar size in the Indian market ($USD42.81K).

Compensatie versus inkomsten: Umesh's compensation has been consistent with company performance over the past year.

CEO

Umesh Sandu (57 yo)

6.4yrs

Tenure

₹8,448,000

Compensatie

Mr. Umesh Bhaskar Sandu serves as the Managing Director and Executive Director of Sandu Pharmaceuticals Limited since June 2, 2018 and served as its Company Secretary.

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Umesh Sandu	MD & Executive Director	6.4yrs	₹8.45m	14.37% ₹ 78.2m
Vijay Kajarekar	Chief Financial Officer	less than a year	₹894.29k	geen gegevens
Pratika Mhambray	Compliance Officer & Company Secretary	9.6yrs	₹848.00k	geen gegevens

6.4yrs

Gemiddelde duur

Ervaren management: 524703's management team is seasoned and experienced (6.4 years average tenure).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Umesh Sandu	MD & Executive Director	6.4yrs	₹8.45m	14.37% ₹ 78.2m
Shashank Sandu	Non-Executive Director	13.4yrs	geen gegevens	14.17% ₹ 77.1m
Jayshree Sandu	Non-Executive Non-Independent Women Director	less than a year	geen gegevens	7.63% ₹ 41.5m
Shubhada Sandu	Non-Executive Director	9.6yrs	geen gegevens	0.10% ₹ 563.3k
Ajit Kantak	Non-Executive Independent Director	1.3yrs	geen gegevens	geen gegevens
Balaram Vishwanathan	Non Executive Independent Chairman	1.3yrs	geen gegevens	geen gegevens
Vijay Kottapall	Non-Executive Independent Director	less than a year	geen gegevens	geen gegevens

1.3yrs

Gemiddelde duur

60yo

Gemiddelde leeftijd

Ervaren bestuur: 524703's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.

Sandu Pharmaceuticals Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Less than half of directors are independent

Sandu Pharmaceuticals Limited Announces CFO Changes

Sandu Pharmaceuticals Limited Announces CFO Changes

Sandu Pharmaceuticals Limited, Annual General Meeting, Sep 30, 2023

Insufficient new directors

Insufficient new directors

Recent updates

Upcoming dividend of ₹0.80 per share

First quarter 2025 earnings released: EPS: ₹0.17 (vs ₹0.11 in 1Q 2024)

Dividend increased to ₹0.80

Sandu Pharmaceuticals Limited announces Annual dividend, payable on October 25, 2024

Sandu Pharmaceuticals Limited to Report Q1, 2025 Results on Aug 12, 2024

Full year 2024 earnings released: EPS: ₹1.51 (vs ₹1.61 in FY 2023)

Sandu Pharmaceuticals Limited to Report Q4, 2024 Results on May 30, 2024

Less than half of directors are independent

Third quarter 2024 earnings released: EPS: ₹0.21 (vs ₹0.51 in 3Q 2023)

Sandu Pharmaceuticals Limited to Report Q3, 2024 Results on Feb 14, 2024

Sandu Pharmaceuticals Limited Announces CFO Changes

Sandu Pharmaceuticals Limited Announces CFO Changes

New major risk - Share price stability

Second quarter 2024 earnings released: EPS: ₹0.57 (vs ₹0.64 in 2Q 2023)

Investor sentiment improves as stock rises 19%

Sandu Pharmaceuticals Limited to Report Q2, 2023 Results on Nov 13, 2023

Investor sentiment improves as stock rises 23%

Upcoming dividend of ₹0.75 per share at 1.1% yield

Full year 2023 earnings released: EPS: ₹1.62 (vs ₹1.99 in FY 2022)

New minor risk - Financial data availability

Sandu Pharmaceuticals Limited, Annual General Meeting, Sep 30, 2023

Sandu Pharmaceuticals Limited to Report Q1, 2024 Results on Aug 14, 2023

Third quarter 2023 earnings released: EPS: ₹0.51 (vs ₹0.57 in 3Q 2022)

Sandu Pharmaceuticals Limited to Report Q3, 2023 Results on Feb 14, 2023

Second quarter 2023 earnings released: EPS: ₹0.64 (vs ₹0.57 in 2Q 2022)

Insufficient new directors

Sandu Pharmaceuticals Limited to Report Q2, 2022 Results on Nov 14, 2022

Sandu Pharmaceuticals Limited Approves Dividend for the Financial Year Ended March 31, 2022

Upcoming dividend of ₹0.75 per share

Sandu Pharmaceuticals Limited Recommends Dividend for the Financial Year Ended 31 March 2022

Sandu Pharmaceuticals Limited to Report Q1, 2023 Results on Aug 12, 2022

Full year 2022 earnings released: EPS: ₹1.99 (vs ₹1.54 in FY 2021)

Sandu Pharmaceuticals Limited to Report Q4, 2022 Results on May 30, 2022

Insufficient new directors

Investor sentiment improved over the past week

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Sandu Pharmaceuticals Limited Approves Appointment of K Vinay Kumar as Chairman

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS ₹0.57 (vs ₹0.56 in 2Q 2021)

Insufficient new directors

Sandu Pharmaceuticals Limited Resumed Manufacturing Operation to the Extent of 100% at Pilerne Industrial Estate, Goa

Sandu Pharmaceuticals Limited Resumes Partial Manufacturing Operation

Sandu Pharmaceuticals Limited Resumes Partial Manufacturing Operation

Sandu Pharmaceuticals Limited Announces Closure of Goa Factory

Investor sentiment improved over the past week

Sandu Pharmaceuticals Limited announced that it expects to receive INR 13.319198 million in funding from Akshath Finvest & Properties Pvt. Ltd., Neelambar leasing and Finvest Private, Sanbro Marketting Services Private Limited

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS ₹0.41 (vs ₹0.22 in 3Q 2020)

Sandu Pharmaceuticals Limited to Report Q3, 2021 Results on Feb 13, 2021

New 90-day high: ₹40.30

Investor sentiment improved over the past week

Market bids up stock over the past week

New 90-day high: ₹32.65

Market bids up stock over the past week

Second quarter 2021 earnings released: EPS ₹0.56

Sandu Pharmaceuticals Limited to Report Q2, 2021 Results on Nov 13, 2020

Market pulls back on stock over the past week

New 90-day high: ₹25.85

First quarter earnings released

Full year earnings released - EPS ₹1.02

Sandu Pharmaceuticals Limited to Report Q1, 2021 Results on Sep 14, 2020

Sandu Pharmaceuticals Limited announced that it expects to receive INR 9.595 million in funding from Akshath Finvest & Properties Pvt. Ltd., and other investors

New 90-day high - ₹22.75

Full year earnings released - EPS ₹1.02

Sandu Pharmaceuticals Limited to Report Q4, 2020 Results on Jul 31, 2020

Analyse CEO-vergoeding

CEO

Tenure